Sonoclot Analyzer, ACT Machine India, Thromboelastography, Cardiac Surgery, Liver Transplant

 [2003 SPA/JSPA Joint Meeting SR16] Platelet Function and Coagulability during Cardiopulmonary Bypass in Children: Analysis by Sonoclot with a Heparinase Glass-Beads Cuvette. Y. Toyoshima, A. Kimura, M. Nawa, S. Kawana Departments of Anesthesiology, Hokkaido Children’s Hospital and Medical Center   Introduction : It has been difficult to evaluate platelet function during cardiopulmonary bypass (CPB) due to the effect of heparin. Sonoclot analysis with a heparinase glass-beads cuvette enables bedside monitoring of platelet function and coagulability in heparinized blood. In this preliminary study, we measured platelet function and coagulability during CPB in children with congenital heart disease (CHD).   Methods : Approval for the study was obtained from our institutions review board, and informed consent was obtained from the parents of the children. The subjects were five children with CHD (1.2-4.5 yrs old) who were scheduled to undergo cardiac surgery under CPB. Bloo

Disseminated Intravascular Coagulation India DIC Bleeding Hyperfibrinolysis Sonoclot For More information please visit: www.lifediagnostica.com/contact_us

Disseminated Intravascular Coagulation (DIC) The DIC process can be divided into three stages: • Hypercoagulable (Stage I) • Secondary fibrinolytic (Stage II) • Hypocoagulable (Stage III) Hypercoagulable (Stage I) DIC is commonly initiated through release of tissue factor (TF) and FVIIa activation of the extrinsic pathway, resulting in a deposition of thrombin in the microcirculation system. TF is normally contained within the cellular membrane and encrypted. However, traumatic tissue injury, required major resuscitation, or major surgery, exposes TF to the bloodstream. TF expression can also occur when monocytes are activated by sepsis, endotoxin, the presence of cancerous cells, or in pregnancy when amniotic fluid penetrates the maternal blood stream. In summary, the release of TF, together with FVIIa, initiates the extrinsic coagulation cascade and, if it is not anticoagulated accordingly, with heparin low molecular weight heparin (LMWH), or activated prote

For More information www.lifediagnostica.com

A-535 2002 Differential Effects of Hirudin and Heparin on the Whole Blood Clot Formation Jaime Torres, M.D.; Nobukazu Sato, M.D.; Kenichi A. Tanaka, M.D.; Fania Szlam, M.M.S.; Jerrold H. Levy, M.D. Anesthesiology, Emory University School of Medicine, Atlanta, Georgia Introduction: Although heparin (Hep) is widely used for anticoagulation during cardiac or vascular surgery, some patients may suffer from serious complications such as heparin-induced thrombocytopenia. Recombinant hirudin (rHir), a direct thrombin inhibitor, is used as a heparin alternative1, 2. However, the effects of rHir on the whole blood clot formation is not completely understood. Therefore, we designed a study to compare the effects of rHir and Hep using the Sonoclot, a viscoelastic coagulation monitor. Methods: After institutional approval and informed consent, 5 healthy volunteers were included in this protocol. Blood samples were collected int

J Cardiothorac Vasc Anesth. 2008 Oct;22(5):670-4. Epub 2008 Mar 24. Sonoclot analysis in coronary artery surgery: a comparison between patients with unstable coronary artery disease treated with enoxaparin before surgery and patients with stable coronary artery disease not treated with enoxaparin. Pleym H, Wahba A, Bjella L, Stenseth R. Department of Cardiothoracic Anesthesia and Intensive Care, St Olav University Hospital, Trondheim, Norway. hilde.pleym@stolav.no Abstract OBJECTIVES: To investigate whether perioperative Sonoclot analyses could identify differences in hemostatic function between a group of patients with unstable coronary artery disease treated with low-molecular-weight heparin until the evening before surgery and a group of patients with stable coronary artery disease not treated with lowmolecular-weight heparin. DESIGN: Prospective and observational investigation. SETTING: A university hospital, single institution. PARTICIPANTS: Patien

Sonoclot Analyzer and Platelet Aggregometry Detect Platelet Receptor (GPIIb/IIIa) Blockade Yue Dong, M.D.; Gregory A. Nuttall, M.D.; William C. Oliver, M.D.; Mark H. Ereth, M.D. Anesthesiology, Mayo Clinic, Rochester, Minnesota, United States [Background] Abciximab blocks the major platelet surface receptor (GPIIb/IIIa), which is critical to platelet aggregation. Practical means to monitor platelet function in patients on abciximab undergoing emergency cardiac surgery is needed. [Methods] After Institutional Review Board approval and informed consent, blood samples were drawn from 20 healthy volunteers. Celite activated Sonoclot analysis and ADP activated Platelet Poor Plasma (PRP) aggregometry were completed after addition of abciximab. The Sonoclot analysis and ADP activated PRP aggregometry were used to detect platelet function. The data was analyzed by student's t test and P<0.05 is statistically significan

Monitoring fondaparinux (Low Molecular Weight Heparin Management / LMWH) with the Sonoclot Nilsson, Caroline U; Engström, Martin Abstract Fondaparinux is a new anticoagulant that interacts with antithrombin III and activated coagulation factor X resulting in an inhibition of the coagulation system. It has been successful in doses of 2.5 mg for thromboprophylaxis as well as in higher therapeutic doses of 5-7.5 mg. No optimal method for monitoring the effects of fondaparinux has been proposed. The aim of the present study was to investigate whether a viscoelastic coagulation analyzer, the Sonoclot (Sienco, Denver, Colorado, USA), could be used for in-vitro monitoring of fondaparinux. Different concentrations of fondaparinux were added in vitro to whole blood taken from eight volunteers. The blood samples mixed with the various amounts of fondaparinux were analyzed using the Sonoclot. The whole-blood activated partial thromboplastin time with the Hemochron Jr (ITC, Ediso

Celite-activated viscometer Sonoclot can measure the suppressive effect of tranexamic acid on hyperfibrinolysis in cardiac surgery Abstract Purpose. To investigate the usefulness of the celiteactivated viscometer Sonoclot for monitoring fibrinolytic status in cardiac surgery, we demonstrated the effectiveness of high doses of tranexamic acid, an antifibrinolytic agent, in reducing postoperative bleeding. Methods. Thirty-two American Society of Anesthesiologists (ASA) physical status III patients who required cardiac surgery with cardiopulmonary bypass (CPB) were studied. Anesthesia was induced by a high dose of fentanyl and midazolam with oxygen and was maintained by the intermittent administration of these agents. Patients were divided into two groups: the control group ( n = 15) and patients receiving tranexamic acid (TA; n = 17). The TA group received a high dose (50 mg/kg) of TA twice, once before and once after CPB. The percentage diminishing rate of the Sonoclot tracing

Disseminated Intravascular Coagulation (DIC) The DIC process can be divided into three stages: • Hypercoagulable (Stage I) • Secondary fibrinolytic (Stage II) • Hypocoagulable (Stage III) Hypercoagulable (Stage I) DIC is commonly initiated through release of tissue factor (TF) and FVIIa activation of the extrinsic pathway, resulting in a deposition of thrombin in the microcirculation system. TF is normally contained within the cellular membrane and encrypted. However, traumatic tissue injury, required major resuscitation, or major surgery, exposes TF to the bloodstream. TF expression can also occur when monocytes are activated by sepsis, endotoxin, the presence of cancerous cells, or in pregnancy when amniotic fluid penetrates the maternal blood stream. In summary, the release of TF, together with FVIIa, initiates the extrinsic coagulation cascade and, if it is not anticoagulated accordingly, with heparin low molecular weight heparin (LMWH), or activated protein C

Sonoclot - ACT Machine India Sonoclot SC1 Analyzer calculates onset of ACT and Clot Rate for in vitro coagulation studies by monitoring mechanical changes that occur to blood samples during hemostasis. Features: o ACT & Clot Rate Results o Separate Results for Factor Xa & Thrombin (IIa) Inhibition o Information on Coagulation Factors & Fibrinogen in one Simple Test o Accurate Heparin Anti-Coagulation Management o Residual Heparin Detection o Low Molecular Weight Heparin Management o Improved Hemostasis Management o Reduced Usage of Blood Products o Portable for use in OR, Cath Lab, ICU or Lab. o Simple QC Procedure o Microprocessor Controlled o On Board Data Storage and Computer Connectivity More Details on: http://www.lifediagnostica.com/

Sonoclot SC1 Analyzer calculates onset of ACT and Clot Rate for in vitro coagulation studies by monitoring mechanical changes that occur to blood samples during hemostasis. The mechanism is a tubular probe that moves up and down within a blood sample. This produces a series of electronic signals that are processed by a microcomputer. Sonoclot SC1 incorporates Sienco's patented whole blood viscoelastic clot detection mechanism. It provides effective clinical hemostasis management for operating rooms, coagulation labs, STAT labs, and intensive care units. For More Details please follow: http://www.lifediagnostica.com/